Lilly Signs Potential $1 Billion Alzheimer’s Deal With AlzeCure

Eli Lilly and Company has licensed global rights to AlzeCure Pharma’s ACD680, an investigational gamma-secretase modulator (GSM) from the Alzstatin platform. The deal includes a $10 million upfront payment, potential development and commercial milestone payments exceeding $1 billion, and tiered mid-single-digit royalties on future sales. Excluding royalties, the agreement’s total value could surpass $1 billion. The transaction remains subject to customary closing conditions, including review under Sweden’s foreign direct investment regulations.

Scientific Rationale

ACD680 belongs to a class of small molecules known as GSMs, which modulate the processing of amyloid precursor protein. Unlike plaque-clearing antibodies, GSMs reduce production of the aggregation-prone amyloid-beta 42 (Aβ42) peptide while increasing shorter fragments such as Aβ37 and Aβ38, which are considered less pathogenic. This mechanism is supported by genetic evidence linking amyloid processing pathways to Alzheimer’s disease risk and progression.

By acting upstream in the amyloid cascade, GSMs could help limit the re-accumulation of harmful amyloid in the brain and may complement existing anti-amyloid treatment strategies.

Clinical and Development Context

AlzeCure developed ACD680 within its Alzstatin platform, which focuses on disease-modifying therapies targeting the underlying pathology of Alzheimer’s disease. Although detailed clinical results for ACD680 have not been disclosed, the agreement highlights continued industry interest in genetically validated Alzheimer’s targets.

Unlike earlier γ-secretase inhibitors, GSMs selectively shift amyloid production toward shorter peptide forms while preserving normal enzyme activity, an approach intended to address safety challenges that historically limited this therapeutic class. The mechanism also complements Lilly’s broader Alzheimer’s portfolio, which includes antibody-based therapies targeting amyloid plaques.

Competitive Landscape

The Alzheimer’s field has recently seen approvals of plaque-clearing antibodies such as Leqembi and Kisunla. However, these therapies are generally used after substantial amyloid accumulation has already occurred. GSMs represent a differentiated strategy that targets amyloid production earlier in the disease process, potentially offering another approach to slowing disease progression.

Lilly’s investment reflects a broader industry trend toward genetically validated mechanisms and diversification beyond antibody-based therapies.

Clinical Implications

Johan Sandin, Chief Scientific Officer of AlzeCure Pharma, said the gamma-secretase modulators developed through the Alzstatin platform are small-molecule therapies built on a mechanism with a strong genetic link to Alzheimer’s disease.

Martin Jönsson, Chief Executive Officer of AlzeCure Pharma, said the Alzstatin compounds could help counter the re-accumulation of harmful amyloid in the brain and may have potential as preventive therapies in the future. He also described the agreement with Lilly as an important milestone for both the Alzstatin program and AlzeCure, reflecting growing interest in gamma-secretase modulation as a therapeutic strategy for Alzheimer’s disease.

For AlzeCure, the partnership delivers significant non-dilutive funding while providing external validation of its Alzheimer’s research platform.

Path Forward

Following completion of the transaction, Lilly will assume responsibility for the global development and commercialization of ACD680. The agreement strengthens Lilly’s Alzheimer’s franchise by adding a genetically supported mechanism that complements its existing amyloid-focused programs.

For AlzeCure, the deal provides resources to advance its broader CNS pipeline while maintaining its focus on disease-modifying therapies. Investors and researchers will closely monitor Lilly’s development plans for ACD680 as the program advances through clinical development.

Reference

alzecure-pharma-enters-into-a-collaboration-and-out-licensing-agreement-with-lilly-for-alzheimers-project.pdf